Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia

Phase I study of ADI‐PEG20 plus low‐dose cytarabine for the treatment of acute myeloid leukemia

Abstract Most acute myeloid leukemia (AML) cells are argininosuccinate synthetase‐deficient. Pegylated arginine deiminase (ADI‐PEG20) monotherapy depletes circulating arginine, thereby selectively inducing tumor cell death. ADI‐PEG20 was shown to induce complete responses in ~10% of relapsed/refract...

Full description

Bibliographic Details
Main Authors: Hui‐Jen Tsai, Hui‐Hua Hsiao, Ya‐Ting Hsu, Yi‐Chang Liu, Hsiao‐Wen Kao, Ta‐Chih Liu, Shih‐Feng Cho, Xiaoxing Feng, Amanda Johnston, John S. Bomalaski, Ming‐Chung Kuo, Tsai‐Yun Chen
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:Cancer Medicine
Subjects:
acute myeloid leukemia
arginine deprivation
low‐dose cytarabine
pegylated arginine deiminase (ADI‐PEG20)
phase I
Online Access:https://doi.org/10.1002/cam4.3871

Internet

https://doi.org/10.1002/cam4.3871

Similar Items